Navigation Links
Senex Biotechnology Announces Presentation of Alzheimer's Disease Drug Discovery Effort
Date:10/15/2007

NEW YORK, Oct. 15 /PRNewswire/ -- Senex Biotechnology, Inc. presented today new results from its drug discovery program at the 8th International Conference on Alzheimer's Disease Drug Discovery in New York. Dr. Igor Roninson, the President of Senex, described the identification of the first drug candidates that block aging cells from producing excessive amounts of several proteins involved in Alzheimer's disease, including: amyloid precursor protein (APP); BACE1 that converts APP to beta-amyloid; and tissue transglutaminase (TGM2) that cross-links beta-amyloid to form amyloid plaques. Excessive accumulation of beta amyloid and amyloid plaques is believed to cause the symptoms of Alzheimer's disease. The signaling pathway targeted by Senex compounds was also implicated in cancer and some other diseases of old age, providing additional disease targets for drug development.

Because of their unique mechanism of action, Senex drug candidates only inhibit aging-associated increases in Alzheimer's disease-associated proteins, and therefore, may be better tolerated than drug candidates that reduce APP and APP-converting enzyme activities below normal levels.

In a study first reported by Dr. Roninson in 2000 and awarded the first annual Life Extension Prize, human cells that cease dividing were discovered to increase the production of many proteins that promote the development of Alzheimer's disease, cancer and several other diseases associated with old age. Senex scientists have developed and applied a proprietary high-throughput screening assay for compounds that prevent the induction of such proteins in non-dividing cells. The lead class of active compounds identified by Senex inhibits the induction of disease-associated genes and changes the typical "aged" (senescent) appearance of cells that cease dividing. These compounds also increase the activity of tumor-suppressor proteins that prevent the development of cancers. Senex is planning to develop its proprietary compounds as pharmaceutical agents.

Geneticist Richard Davidson, Ph.D., former Head of the Department of Molecular Genetics at the University of Illinois at Chicago and currently Administrative Director of Kimmel Cancer Center at Thomas Jefferson University in Philadelphia, commented, "The relatively recent discovery that aging cells overproduce proteins that cause Alzheimer's and other age-related diseases was one of the most striking findings in the field of functional genomics, made possible by the sequencing of the human genome. It is exciting to see how rapidly a genomics discovery can lead to the development of pharmaceuticals that may potentially help seniors to lead healthier lives."

About Senex Biotechnology

Senex Biotechnology, Inc. is a privately-held drug discovery and development company in Albany, NY, which is developing drugs against cancer and major diseases of old age, by targeting signaling pathways activated in the process of cell senescence (aging).

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future the financial performance and clinical and business prospects for Senex products, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete the optimization and development of our drug product candidates; manufacturing capabilities or other factors; and other risk factors. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

For more information, contact info@senexbio.com.


'/>"/>
SOURCE Senex Biotechnology, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Olympics of biotechnology has international flavor
2. Making Wisconsin the biotechnology leader
3. Let the olympics of biotechnology in the Midwest begin!
4. The mushrooming of biotechnology in the U.S.
5. 42 days until the 2006 Olympics of Biotechnology in Chicago
6. Third coast of biotechnology makes strong showing at VC conference
7. State wants to encourage industrial biotechnology
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. First graduates boon to Wisconsin biotechnology
10. Americas Third Coast nurtures biotechnology
11. Florida: Investing Heavily in Biotechnology - Governor uses state funds to attract large biotech companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... KCAS Bioanalytical ... a 0.2 ng/mL lower limit (LLOQ) assay for nicotine and two key metabolites ... the ultra-low trace nicotine assay meets additional needs of tobacco industry that need ...
(Date:4/27/2017)... ... April 27, 2017 , ... This month ... consent (eConsent) solution that simplifies research studies, accelerates study startup, and improves participant ... Q Consent™ is the first and only IRB-integrated eConsent solution . , ...
(Date:4/27/2017)... ... April 27, 2017 , ... Volunteers ... other scientists, researchers, engineers, and industry professionals in visiting U.S. Congressional offices in ... compete in the world photonics industry. , This year, National Photonics Initiative ...
(Date:4/26/2017)... SC (PRWEB) , ... April 26, 2017 , ... ... mind, has teamed up with NASA to showcase the future of deep space ... Launch System (SLS) rocket and Orion spacecraft and includes a guest appearance by ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):